Claimed effect · Semaglutide

Does Semaglutide help with BMI in children aged 6–11?

B
Grade B — probable, not settled1 phase 3 RCT topline (n=165) · effect size: moderate
Short answerProbable, not settled. Human data exist (1 phase 3 RCT topline (n=165)) and mostly agree, showing a moderate effect — but too few, too small, or not yet peer-reviewed for a firm answer. STEP Young, reported by press release on 7 September 2026: the primary BMI endpoint was met at 68 weeks, and 40.4% of children on semaglutide finished below the obesity threshold against 0% on placebo. Novo Nordisk reports no growth or pubertal safety signal. Graded B until the paper appears; full data promised for November 2026.

What the studies show

STEP Young, reported by press release on 7 September 2026: the primary BMI endpoint was met at 68 weeks, and 40.4% of children on semaglutide finished below the obesity threshold against 0% on placebo. Novo Nordisk reports no growth or pubertal safety signal. Graded B until the paper appears; full data promised for November 2026.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Novo Nordisk. STEP Young phase 3 trial of semaglutide in children aged 6 to under 12 with obesity: topline results.Press release, 7 Sep 2026165 children, 68 weeks. Topline; not peer-reviewed. Full results due at ObesityWeek, 14–17 Nov 2026.

In context

Semaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes and, at a higher dose, for weight management. In large randomised trials it produces roughly 15% average weight loss over 68 weeks and reduces major cardiovascular events in people with existing heart disease. Gastrointestinal side effects are common and are the main reason people stop. It is a prescription medicine; products sold outside that channel are unlicensed copies.

Semaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Semaglutide proven to help with BMI in children aged 6–11?
Not yet settled. 1 phase 3 RCT topline (n=165) — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
STEP Young, reported by press release on 7 September 2026: the primary BMI endpoint was met at 68 weeks, and 40.4% of children on semaglutide finished below the obesity threshold against 0% on placebo. Novo Nordisk reports no growth or pubertal safety signal. Graded B until the paper appears; full data promised for November 2026.
Is Semaglutide approved for this?
Semaglutide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Semaglutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →